Castle Biosciences Inc logo

Castle Biosciences (CSTL) — Congressional Trading Activity

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Members Trading

1

All-time in Castle Biosciences

Buyers vs Sellers

0Buyers/0Sellers

Members buying vs selling · last 90 days

Trades (90d)

0

Disclosed in the last 90 days

Avg Member Return

—

Top performers, TTM

Stock Report
$1K - $15K
StockSaleDemocratNew JerseyApr 17, 2022Mar 15, 2022House
$1K - $15K
StockPurchase—CaliforniaJan 11, 2021Dec 23, 2020House
$1K - $15K
StockPurchaseDemocratNew JerseyJan 07, 2021Dec 21, 2020House